McKesson and CD&R agree $5.8bn deal for infusion therapy firm Option Care Health

Drug distributor McKesson and private equity firm Clayton Dubilier & Rice agreed on Tuesday to buy infusion therapy provider Option Care Health in a deal worth about $5.8 billion including debt (https://www.reuters.com/legal/transactional/mckesson-cdr-buy-infusion-therapy-provider-option-care-health-58-billion-deal-2026-10-06/).

The per-share offer price of $32.05 represents a 37.1% premium to Option Care’s last closing price (https://www.reuters.com/legal/transactional/mckesson-cdr-buy-infusion-therapy-provider-option-care-health-58-billion-deal-2026-10-06/).

At the closing of the transaction, CD&R will hold a majority ownership interest while McKesson takes a minority stake. Option Care Health will remain a separate company led by its own management team (https://www.reuters.com/legal/transactional/mckesson-cdr-buy-infusion-therapy-provider-option-care-health-58-billion-deal-2026-10-06/).

The deal is the latest in McKesson’s push to expand its healthcare services footprint, and marks another private equity buyout of a home health services provider following the Enhabit deal (https://www.reuters.com/legal/transactional/mckesson-cdr-buy-infusion-therapy-provider-option-care-health-58-billion-deal-2026-10-06/).

Option Care Health (OPCH.O) is one of the largest independent providers of home and alternate-site infusion services in the United States.